At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
In Brief
A Phase 2 clinical trial evaluating Oxytocin nasal spray and Placebo nasal spray for Obesity and 4 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is an urgent need to test novel pharmacologic interventions to prevent disability and loss of independence. Oxytocin is a pituitary hormone released during parturition and lactation that is also known to suppress appetite in rodents and humans; and, recent small studies have found that intranasal oxytocin reduces body weight in adults. We propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and increase muscle mass in older subjects with sarcopenic obesity.
Study Details
Timeline
Interventions
Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)